IDEAYA Biosciences (IDYA) Shares Soar 1.92% on FDA Meeting Success

IDEAYA Biosciences (IDYA) shares rose to their highest level since March 2025 today, with an intraday gain of 1.92%.

IDEAYA Biosciences' stock price has seen significant movement recently, driven by several key developments. On April 14, 2025, the company announced a successful FDA Type D meeting regarding the Phase 3 registrational trial design for Darovasertib as neoadjuvant therapy for primary uveal melanoma. This regulatory progress is likely to boost investor confidence, as it indicates that the company is making strides in the approval process for this potential treatment.

In addition to regulatory progress, institutional investors have shown increased interest in IDEAYA Biosciences. Recent filings indicate that Barclays PLC and Jump Financial LLC have increased their holdings in the company. This institutional buying, along with insider purchases, suggests a growing belief in the company's future prospects. Such investor sentiment can have a positive impact on the stock price, as it reflects confidence in the company's long-term growth potential.